Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells
Tedeschi, P M, Markert, E K, Gounder, M, Lin, H, Dvorzhinski, D, Dolfi, S C, Chan, L L-Y, Qiu, J, DiPaola, R S, Hirshfield, K M, Boros, L G, Bertino, J R, Oltvai, Z N, Vazquez, A
Published in Cell death & disease (01.10.2013)
Published in Cell death & disease (01.10.2013)
Get full text
Journal Article
1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
Schadendorf, D., Tawbi, H.A., Hodi, F.S., Lipson, E.J., Ascierto, P.A., Medina Soto, F.A., Maio, M., Hernberg, M., Mackiewicz, J., Prey, S., Mujika Eizmendi, M.K., Atkinson, V.G., Hassel, J.C., Cinat, G., Keidel, S., Rodriguez, S., Wang, P.T., Dolfi, S., Long, G.V.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)
Long, G.V., Desai, K., Tang, T., Weber, J.S., Dolfi, S., Ritchings, C., Huang, S-P., Bolisetty, M., Sausen, M., Del Vecchio, M., Larkin, J., Baden, J., Balli, D., Chang, H., Loffredo, J., Zhang, N., Wind-Rotolo, M., Tenney, D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
Hodi, F.S., Tawbi, H.A., Lipson, E.J., Schadendorf, D., Ascierto, P.A., Matamala, L.A., Salman, P., Gutierrez, E.C., Rutkowski, P., Gogas, H.J., Lao, C.D., Menezes, J., Dalle, S., Arance Fernandez, A.M., Grob, J.J., Keidel, S., Rodriguez, S., Wang, P., Dolfi, S., Long, G.V.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047
Lipson, E.J., Dolfi, S., Tang, H., Gogas, H., Tawbi, H.A., Hodi, F.S., Ascierto, P.A., Gutierrez, E.C., Schadendorf, D., Medina Soto, F.A., Rutkowski, P., Murillo Ramirez, E., Maio, M., Xu, Y., Desai, K., Yu, A., Demers, K., Miller-Moslin, K., Long, G.V., Garnett-Benson, C.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020
Ascierto, P.A., Tang, H., Dolfi, S., Nyakas, M.S., Svane, I-M., Couselo, E. Muñoz, Grob, J.J., Gomez-Roca, C.A., Sileni, V. Chiarion, Peltola, K., Larkin, J., Melero, I., Callahan, M., Dummer, R., Djidel, P., Warad, D., Lipson, E.J., Garnett-Benson, C.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article
1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Long, G.V., Hodi, F.S., Lipson, E.J., Schadendorf, D., Ascierto, P.A., Medina Soto, F.A., Maio, M., Hernberg, M., Mackiewicz, J., Prey, S., Mujika Eizmendi, M.K., Atkinson, V.G., Hassel, J.C., Cinat, G., Ratto, B., Rodriguez, S., Wang, P.T., Dolfi, S., Tawbi, H.A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Abstract P3-07-02: Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
Hirshfield, KM, Paratala, BS, Hindoyan, A, Dolfi, SC, Yilmazel, B, Schrock, A, Gay, L, Ali, SM, Ross, JS, Williams, CB, Nair, P, Ganesan, S, Leyland-Jones, B
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article